Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
Subtype terms (2)
More specific conditions that are subtypes of Poliomyelitis in the MeSH hierarchy.
- Poliomyelitis, Bulbar
- Postpoliomyelitis Syndrome
8 drugs (6 approved, 2 experimental)
Drugs by status
Approved for this indication (15)
- norepinephrine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- inactivated poliovirus type 2 vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- live oral poliovirus type 1, 2 and 3
- measles and inactivated polio vaccine
- anti-poliomyelitis serum
- bivalent oral polio vaccine (bopv), type 1 and type 3
- monovalent oral polio vaccines (mopv1)
- monovalent oral polio vaccines (mopv2)
- polio, inactivated poliovirus vaccine
- inactivated sabin strain polio virus
- novel oral polio vaccine type 1 (nopv1)
- novel opv2
- Inactivated polio virus - Enhanced
Phase 4 trials (8)
- diphtheria, tetanus and whole cell pertussis vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- technetium tc-99m pentetate kit
- hepa-l
Phase 3 trials (20)
- diphtheria, tetanus, and poliovirus vaccine
- diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
- menitorix
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- Measles, Mumps and Rubella Vaccine, Live
- acellular pertussis vaccine
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- inactivated influenza vaccine
- live attenuated varicella vaccine
- pneumococcal 7-valent conjugate vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- measles, mumps, rubella, varicella vaccine
- bivalent opv
- diphtheria toxoid
- tetanus toxoid
- human rotavirus, live attenuated
- novel oral polio vaccine type 2 (nopv2)
- Monovalent group C meningococcal vaccine
- Bivalent group A and C meningococcal vaccine
Phase 2 trials (8)
Phase 1 trials (1)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (28)
- Sanofi
- Sanofi-Aventis
- GlaxoSmithKline
- Fidec Corporation
- National Institutes of Health (NIH)
- Centers for Disease Control and Prevention, China
- World Health Organization
- Vilnius University
- Aga Khan University
- University of Chile
- University of Colorado, Denver
- Tribhuvan University
- International Center for Diarrheal Disease Research
- Government of Pakistan
- Government of China
- Medical Research Council, The Gambia
- China National Biotec Group Co., Ltd
- Bill and Melinda Gates Foundation
- AJ Vaccines A/S
- Trust for Vaccines and Immunization, Pakistan
- Peshawar Medical College
- Government of Norway
- Government of India
- United Nations
- Centers for Disease Control and Prevention (CDC)
- Christian Medical College, Vellore, India
- PATH
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (26)
- Merck
- Grifols
- Bilthoven Biologicals
- INC Research
- LG
- NanoPass Technologies Ltd
- Serum Institute of India Pvt. Ltd.
- Sinovac Biotech Co., Ltd
- Vaxtrials S.A.
- United States Army
- University Hospital, Basel, Switzerland
- Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.
- Osaka University
- University of Bern
- Statens Serum Institut
- University of Basel
- Boryung Pharmaceutical Company
- Mitsubishi Tanabe
- Eulji University
- CASMU Polyclinic 8 de Octubre 3310 Montevideo, Uruguay
- Larix A/S
- Government of Bangladesh
- Beijing Tiantan Bio Co., Ltd
- Government of Vietnam
- Bureau of Science and Technology of Guangxi Province, China
- People's Liberation Army of China
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (5)